Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex

Elbert D. Glover, David P.L. Sachs, Maxine L. Stitzer, Stephen Israel Rennard, William C. Wadland, Ovide F. Pomerleau, Robert T. Nowak, David M. Daughton, Penny N. Glover, John R. Hughes, Janet Gross

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The objective was to evaluate the efficacy of nicotine polacrilex 4 mg for smoking cessation in highly nicotine-dependent cigarette smokers defined by an expired carbon monoxide level of ≥ 15 ppm and a FTQ score of ≥7. The design was a multicenter, double-blind, randomized, parallel, 6-week clinical trial. 563 highly nicotine-dependent cigarette smokers were randomized to one of three treatment interventions, (a) placebo, (b) 2 mg, or (c) 4 mg nicotine polacrilex. Overall, patients assigned to the 4 mg treatment group had a 39% abstinence rate, compared to 33% and 30% quit rate for the 2 mg and placebo groups respectively (p = .191). Results indicate that, in compliant Ss (those using ≥9 pieces of medication/day), 56% of Ss in the 4 mg treatment group were abstinent, compared to 33% and 33% respectively, in the 2 mg and placebo groups (p = .0016). It was concluded that 4 mg nicotine polacrilex is an effective aid to smoking cessation in compliant, highly-dependent smokers.

Original languageEnglish (US)
Pages (from-to)319-332
Number of pages14
JournalAmerican Journal of Health Behavior
Volume20
Issue number5
StatePublished - Dec 1 1996

Fingerprint

Tobacco Use Cessation Products
Smoking Cessation
nicotine
smoking
Placebos
Nicotine
Tobacco Products
Carbon Monoxide
Group
Therapeutics
Clinical Trials
medication

ASJC Scopus subject areas

  • Health(social science)
  • Social Psychology
  • Public Health, Environmental and Occupational Health

Cite this

Glover, E. D., Sachs, D. P. L., Stitzer, M. L., Rennard, S. I., Wadland, W. C., Pomerleau, O. F., ... Gross, J. (1996). Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex. American Journal of Health Behavior, 20(5), 319-332.

Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex. / Glover, Elbert D.; Sachs, David P.L.; Stitzer, Maxine L.; Rennard, Stephen Israel; Wadland, William C.; Pomerleau, Ovide F.; Nowak, Robert T.; Daughton, David M.; Glover, Penny N.; Hughes, John R.; Gross, Janet.

In: American Journal of Health Behavior, Vol. 20, No. 5, 01.12.1996, p. 319-332.

Research output: Contribution to journalArticle

Glover, ED, Sachs, DPL, Stitzer, ML, Rennard, SI, Wadland, WC, Pomerleau, OF, Nowak, RT, Daughton, DM, Glover, PN, Hughes, JR & Gross, J 1996, 'Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex', American Journal of Health Behavior, vol. 20, no. 5, pp. 319-332.
Glover ED, Sachs DPL, Stitzer ML, Rennard SI, Wadland WC, Pomerleau OF et al. Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex. American Journal of Health Behavior. 1996 Dec 1;20(5):319-332.
Glover, Elbert D. ; Sachs, David P.L. ; Stitzer, Maxine L. ; Rennard, Stephen Israel ; Wadland, William C. ; Pomerleau, Ovide F. ; Nowak, Robert T. ; Daughton, David M. ; Glover, Penny N. ; Hughes, John R. ; Gross, Janet. / Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex. In: American Journal of Health Behavior. 1996 ; Vol. 20, No. 5. pp. 319-332.
@article{15da030be4a94739bcf9ca8148e1ab00,
title = "Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex",
abstract = "The objective was to evaluate the efficacy of nicotine polacrilex 4 mg for smoking cessation in highly nicotine-dependent cigarette smokers defined by an expired carbon monoxide level of ≥ 15 ppm and a FTQ score of ≥7. The design was a multicenter, double-blind, randomized, parallel, 6-week clinical trial. 563 highly nicotine-dependent cigarette smokers were randomized to one of three treatment interventions, (a) placebo, (b) 2 mg, or (c) 4 mg nicotine polacrilex. Overall, patients assigned to the 4 mg treatment group had a 39{\%} abstinence rate, compared to 33{\%} and 30{\%} quit rate for the 2 mg and placebo groups respectively (p = .191). Results indicate that, in compliant Ss (those using ≥9 pieces of medication/day), 56{\%} of Ss in the 4 mg treatment group were abstinent, compared to 33{\%} and 33{\%} respectively, in the 2 mg and placebo groups (p = .0016). It was concluded that 4 mg nicotine polacrilex is an effective aid to smoking cessation in compliant, highly-dependent smokers.",
author = "Glover, {Elbert D.} and Sachs, {David P.L.} and Stitzer, {Maxine L.} and Rennard, {Stephen Israel} and Wadland, {William C.} and Pomerleau, {Ovide F.} and Nowak, {Robert T.} and Daughton, {David M.} and Glover, {Penny N.} and Hughes, {John R.} and Janet Gross",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "20",
pages = "319--332",
journal = "American Journal of Health Behavior",
issn = "1087-3244",
publisher = "PNG Publications",
number = "5",

}

TY - JOUR

T1 - Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex

AU - Glover, Elbert D.

AU - Sachs, David P.L.

AU - Stitzer, Maxine L.

AU - Rennard, Stephen Israel

AU - Wadland, William C.

AU - Pomerleau, Ovide F.

AU - Nowak, Robert T.

AU - Daughton, David M.

AU - Glover, Penny N.

AU - Hughes, John R.

AU - Gross, Janet

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The objective was to evaluate the efficacy of nicotine polacrilex 4 mg for smoking cessation in highly nicotine-dependent cigarette smokers defined by an expired carbon monoxide level of ≥ 15 ppm and a FTQ score of ≥7. The design was a multicenter, double-blind, randomized, parallel, 6-week clinical trial. 563 highly nicotine-dependent cigarette smokers were randomized to one of three treatment interventions, (a) placebo, (b) 2 mg, or (c) 4 mg nicotine polacrilex. Overall, patients assigned to the 4 mg treatment group had a 39% abstinence rate, compared to 33% and 30% quit rate for the 2 mg and placebo groups respectively (p = .191). Results indicate that, in compliant Ss (those using ≥9 pieces of medication/day), 56% of Ss in the 4 mg treatment group were abstinent, compared to 33% and 33% respectively, in the 2 mg and placebo groups (p = .0016). It was concluded that 4 mg nicotine polacrilex is an effective aid to smoking cessation in compliant, highly-dependent smokers.

AB - The objective was to evaluate the efficacy of nicotine polacrilex 4 mg for smoking cessation in highly nicotine-dependent cigarette smokers defined by an expired carbon monoxide level of ≥ 15 ppm and a FTQ score of ≥7. The design was a multicenter, double-blind, randomized, parallel, 6-week clinical trial. 563 highly nicotine-dependent cigarette smokers were randomized to one of three treatment interventions, (a) placebo, (b) 2 mg, or (c) 4 mg nicotine polacrilex. Overall, patients assigned to the 4 mg treatment group had a 39% abstinence rate, compared to 33% and 30% quit rate for the 2 mg and placebo groups respectively (p = .191). Results indicate that, in compliant Ss (those using ≥9 pieces of medication/day), 56% of Ss in the 4 mg treatment group were abstinent, compared to 33% and 33% respectively, in the 2 mg and placebo groups (p = .0016). It was concluded that 4 mg nicotine polacrilex is an effective aid to smoking cessation in compliant, highly-dependent smokers.

UR - http://www.scopus.com/inward/record.url?scp=0030516016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030516016&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 319

EP - 332

JO - American Journal of Health Behavior

JF - American Journal of Health Behavior

SN - 1087-3244

IS - 5

ER -